About 30% of multiple myeloma cell line peptides elicited CD8+ T-cell responses.
Proteomic and proteogenomic identification of targetable T-cell antigens in multiple myeloma.
Gabriela Zuleger et al. · Blood advances · 2026
Results
About 30% of peptides from multiple myeloma cell lines stimulated CD8+ T-cell responses.
n = 8
More results
Multiple myeloma (MM) accounts for approximately 12% of all hematologic malignancies and remains incurable despite therapeutic advances.
However, knowledge of targetable tumor antigens, especially neoantigens, is limited.
More results
We applied a mass spectrometry (MS)-based immunopeptidomics approach on primary MM samples (n = 8) and MM cell lines (n = 3), integrating whole-exome and RNA sequencing to comprehensively characterize the MM immunopeptidome and systematically search for TAAs and neoantigens.
“
Conclusion
This study provides the first proteogenomic-based identification of neoantigens in MM, extends the observation of presented Ig-derived neoantigens from B cell lymphoma to MM, and highlights both actionable antigens and barriers to effective TCR-based immunotherapy.